Heidi Chen Appointed Chief Legal Officer at GeneDx Holdings for Strategic Growth

Heidi Chen Joins GeneDx as Chief Legal Officer: A Strategic Move for Future Growth

GeneDx Holdings, a prominent player in the genomic insights sector, announces the appointment of Heidi Chen as its new Chief Legal Officer, effective November 25, 2024. This strategic addition to the executive team comes at a pivotal moment as the company aims to strengthen its position in the rapidly evolving healthcare landscape. Reporting directly to CEO Katherine Stueland, Chen is set to oversee all legal, compliance, and policy functions, while also providing essential guidance on corporate governance and regulatory matters. Her extensive experience and industry expertise, amassed over 30 years, position her as a vital asset for GeneDx as it navigates its next growth phase.

Chen's previous role as General Counsel at Zoetis, where she served for nearly 12 years, showcases her capability in building and leading legal departments in dynamic environments. During her tenure, she was instrumental in shaping the company’s legal framework following its spinoff from Pfizer, overseeing critical functions such as mergers and acquisitions, litigation, and enterprise risk management. Stueland highlights Chen's reputation as a respected leader, emphasizing the importance of her role in aligning legal and business strategies to foster innovation within GeneDx. With her background in human health diagnostics and corporate governance, Chen is expected to bring a wealth of knowledge that will enhance the company's operational strategy.

As she steps into her new role, Chen expresses her commitment to transforming patient care through collaboration and innovation. By leveraging GeneDx's unique position in personalized health insights, Chen aims to improve diagnosis, treatment, and drug discovery, further propelling the company's mission of making precision medicine the standard of care. GeneDx's extensive genomic data sets, particularly in rare diseases, provide a solid foundation for Chen to drive significant advancements in healthcare outcomes. Her appointment underscores the company’s dedication to enhancing its legal and compliance capabilities, which are essential in an industry characterized by rapid changes and regulatory complexities.

In addition to her impressive professional background, Chen's academic credentials include a J.D. from Cornell Law School and a B.S. from Yale University. This educational foundation complements her extensive experience in the legal domain, making her well-equipped to address the multifaceted challenges faced by GeneDx in today's healthcare environment.

GeneDx continues to position itself at the forefront of genomic insights, aiming to enhance health outcomes through innovation and collaboration. For more information on its services and initiatives, interested parties can visit www.genedx.com and follow the company on LinkedIn.